nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—VIIth nerve paralysis—Capecitabine—esophageal cancer	0.0128	0.0259	CcSEcCtD
Cyclobenzaprine—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.0122	0.0248	CcSEcCtD
Cyclobenzaprine—Ileus paralytic—Capecitabine—esophageal cancer	0.0121	0.0246	CcSEcCtD
Cyclobenzaprine—Depressed mood—Capecitabine—esophageal cancer	0.0117	0.0238	CcSEcCtD
Cyclobenzaprine—Ageusia—Cisplatin—esophageal cancer	0.00876	0.0178	CcSEcCtD
Cyclobenzaprine—Bone marrow depression—Capecitabine—esophageal cancer	0.00775	0.0157	CcSEcCtD
Cyclobenzaprine—Dysarthria—Cisplatin—esophageal cancer	0.0075	0.0152	CcSEcCtD
Cyclobenzaprine—Tongue disorder—Capecitabine—esophageal cancer	0.00719	0.0146	CcSEcCtD
Cyclobenzaprine—Ageusia—Capecitabine—esophageal cancer	0.00646	0.0131	CcSEcCtD
Cyclobenzaprine—Bone marrow depression—Methotrexate—esophageal cancer	0.00577	0.0117	CcSEcCtD
Cyclobenzaprine—Dysarthria—Capecitabine—esophageal cancer	0.00553	0.0112	CcSEcCtD
Cyclobenzaprine—Gait disturbance—Capecitabine—esophageal cancer	0.00536	0.0109	CcSEcCtD
Cyclobenzaprine—Coordination abnormal—Capecitabine—esophageal cancer	0.00533	0.0108	CcSEcCtD
Cyclobenzaprine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00526	0.0107	CcSEcCtD
Cyclobenzaprine—Face oedema—Cisplatin—esophageal cancer	0.00497	0.0101	CcSEcCtD
Cyclobenzaprine—Irritability—Cisplatin—esophageal cancer	0.00492	0.00999	CcSEcCtD
Cyclobenzaprine—Mental disability—Capecitabine—esophageal cancer	0.00454	0.00923	CcSEcCtD
Cyclobenzaprine—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00435	0.00883	CcSEcCtD
Cyclobenzaprine—Vascular purpura—Capecitabine—esophageal cancer	0.00425	0.00863	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Cisplatin—esophageal cancer	0.00423	0.00859	CcSEcCtD
Cyclobenzaprine—Dysarthria—Methotrexate—esophageal cancer	0.00412	0.00837	CcSEcCtD
Cyclobenzaprine—Libido decreased—Capecitabine—esophageal cancer	0.0041	0.00832	CcSEcCtD
Cyclobenzaprine—Thirst—Capecitabine—esophageal cancer	0.00399	0.00811	CcSEcCtD
Cyclobenzaprine—Purpura—Capecitabine—esophageal cancer	0.00394	0.00801	CcSEcCtD
Cyclobenzaprine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00391	0.00795	CcSEcCtD
Cyclobenzaprine—Myocardial infarction—Cisplatin—esophageal cancer	0.00389	0.00791	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00389	0.00791	CcSEcCtD
Cyclobenzaprine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00388	0.00788	CcSEcCtD
Cyclobenzaprine—Stomatitis—Cisplatin—esophageal cancer	0.00387	0.00786	CcSEcCtD
Cyclobenzaprine—Diplopia—Capecitabine—esophageal cancer	0.0038	0.00772	CcSEcCtD
Cyclobenzaprine—Osteoarthritis—Capecitabine—esophageal cancer	0.0038	0.00772	CcSEcCtD
Cyclobenzaprine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00377	0.00766	CcSEcCtD
Cyclobenzaprine—Face oedema—Capecitabine—esophageal cancer	0.00367	0.00745	CcSEcCtD
Cyclobenzaprine—Irritability—Capecitabine—esophageal cancer	0.00362	0.00737	CcSEcCtD
Cyclobenzaprine—Urinary retention—Capecitabine—esophageal cancer	0.00361	0.00734	CcSEcCtD
Cyclobenzaprine—Ataxia—Capecitabine—esophageal cancer	0.00357	0.00726	CcSEcCtD
Cyclobenzaprine—Carbamazepine—ABCC2—esophageal cancer	0.00349	0.12	CrCbGaD
Cyclobenzaprine—Gynaecomastia—Methotrexate—esophageal cancer	0.00348	0.00708	CcSEcCtD
Cyclobenzaprine—Gastritis—Capecitabine—esophageal cancer	0.00336	0.00683	CcSEcCtD
Cyclobenzaprine—Tinnitus—Cisplatin—esophageal cancer	0.00332	0.00675	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP1B1—esophageal cancer	0.00332	0.114	CrCbGaD
Cyclobenzaprine—Arrhythmia—Cisplatin—esophageal cancer	0.00318	0.00647	CcSEcCtD
Cyclobenzaprine—Alopecia—Cisplatin—esophageal cancer	0.00315	0.0064	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Capecitabine—esophageal cancer	0.00312	0.00633	CcSEcCtD
Cyclobenzaprine—Flatulence—Cisplatin—esophageal cancer	0.00306	0.00621	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00305	0.0062	CcSEcCtD
Cyclobenzaprine—Weight increased—Capecitabine—esophageal cancer	0.00299	0.00607	CcSEcCtD
Cyclobenzaprine—Vision blurred—Cisplatin—esophageal cancer	0.00292	0.00594	CcSEcCtD
Cyclobenzaprine—Tremor—Cisplatin—esophageal cancer	0.00291	0.00591	CcSEcCtD
Cyclobenzaprine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00288	0.00586	CcSEcCtD
Cyclobenzaprine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00288	0.00586	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00288	0.00585	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00287	0.00583	CcSEcCtD
Cyclobenzaprine—Myocardial infarction—Capecitabine—esophageal cancer	0.00287	0.00583	CcSEcCtD
Cyclobenzaprine—Jaundice—Capecitabine—esophageal cancer	0.00285	0.0058	CcSEcCtD
Cyclobenzaprine—Stomatitis—Capecitabine—esophageal cancer	0.00285	0.0058	CcSEcCtD
Cyclobenzaprine—Osteoarthritis—Methotrexate—esophageal cancer	0.00283	0.00575	CcSEcCtD
Cyclobenzaprine—Malaise—Cisplatin—esophageal cancer	0.0028	0.00569	CcSEcCtD
Cyclobenzaprine—Leukopenia—Cisplatin—esophageal cancer	0.00278	0.00564	CcSEcCtD
Cyclobenzaprine—Protriptyline—ABCB1—esophageal cancer	0.00276	0.0951	CrCbGaD
Cyclobenzaprine—Agranulocytosis—Capecitabine—esophageal cancer	0.00273	0.00555	CcSEcCtD
Cyclobenzaprine—Irritability—Methotrexate—esophageal cancer	0.0027	0.00548	CcSEcCtD
Cyclobenzaprine—Convulsion—Cisplatin—esophageal cancer	0.00269	0.00546	CcSEcCtD
Cyclobenzaprine—Ataxia—Methotrexate—esophageal cancer	0.00266	0.0054	CcSEcCtD
Cyclobenzaprine—Myalgia—Cisplatin—esophageal cancer	0.00264	0.00537	CcSEcCtD
Cyclobenzaprine—Anxiety—Cisplatin—esophageal cancer	0.00263	0.00535	CcSEcCtD
Cyclobenzaprine—Hepatitis—Capecitabine—esophageal cancer	0.00263	0.00534	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00261	0.00531	CcSEcCtD
Cyclobenzaprine—Discomfort—Cisplatin—esophageal cancer	0.00261	0.0053	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Capecitabine—esophageal cancer	0.00261	0.0053	CcSEcCtD
Cyclobenzaprine—Tamoxifen—ABCC2—esophageal cancer	0.00259	0.0891	CrCbGaD
Cyclobenzaprine—Tamoxifen—CYP2A6—esophageal cancer	0.00256	0.0881	CrCbGaD
Cyclobenzaprine—Oedema—Cisplatin—esophageal cancer	0.00253	0.00515	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00253	0.00515	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00248	0.00504	CcSEcCtD
Cyclobenzaprine—Tachycardia—Cisplatin—esophageal cancer	0.00247	0.00502	CcSEcCtD
Cyclobenzaprine—Tinnitus—Capecitabine—esophageal cancer	0.00245	0.00498	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00245	0.00497	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP19A1—esophageal cancer	0.00244	0.0839	CrCbGaD
Cyclobenzaprine—Eosinophilia—Methotrexate—esophageal cancer	0.00242	0.00492	CcSEcCtD
Cyclobenzaprine—Anorexia—Cisplatin—esophageal cancer	0.00241	0.0049	CcSEcCtD
Cyclobenzaprine—Hypotension—Cisplatin—esophageal cancer	0.00237	0.00481	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Capecitabine—esophageal cancer	0.00235	0.00477	CcSEcCtD
Cyclobenzaprine—Alopecia—Capecitabine—esophageal cancer	0.00232	0.00472	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Methotrexate—esophageal cancer	0.00232	0.00472	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00231	0.00469	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Cisplatin—esophageal cancer	0.00227	0.00462	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00227	0.00461	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Cisplatin—esophageal cancer	0.00226	0.00459	CcSEcCtD
Cyclobenzaprine—Flatulence—Capecitabine—esophageal cancer	0.00225	0.00458	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00225	0.00457	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Capecitabine—esophageal cancer	0.00224	0.00455	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Cisplatin—esophageal cancer	0.0022	0.00447	CcSEcCtD
Cyclobenzaprine—Drowsiness—Methotrexate—esophageal cancer	0.00218	0.00443	CcSEcCtD
Cyclobenzaprine—Nortriptyline—PTGS1—esophageal cancer	0.00218	0.075	CrCbGaD
Cyclobenzaprine—Vision blurred—Capecitabine—esophageal cancer	0.00216	0.00438	CcSEcCtD
Cyclobenzaprine—Tremor—Capecitabine—esophageal cancer	0.00214	0.00435	CcSEcCtD
Cyclobenzaprine—Stomatitis—Methotrexate—esophageal cancer	0.00212	0.00432	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00212	0.00431	CcSEcCtD
Cyclobenzaprine—Sweating—Methotrexate—esophageal cancer	0.00209	0.00424	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Cisplatin—esophageal cancer	0.00209	0.00424	CcSEcCtD
Cyclobenzaprine—Malaise—Capecitabine—esophageal cancer	0.00206	0.00419	CcSEcCtD
Cyclobenzaprine—Vertigo—Capecitabine—esophageal cancer	0.00205	0.00418	CcSEcCtD
Cyclobenzaprine—Syncope—Capecitabine—esophageal cancer	0.00205	0.00417	CcSEcCtD
Cyclobenzaprine—Leukopenia—Capecitabine—esophageal cancer	0.00205	0.00416	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Methotrexate—esophageal cancer	0.00203	0.00413	CcSEcCtD
Cyclobenzaprine—Palpitations—Capecitabine—esophageal cancer	0.00202	0.00411	CcSEcCtD
Cyclobenzaprine—Diphenhydramine—PTGS1—esophageal cancer	0.00201	0.0693	CrCbGaD
Cyclobenzaprine—Loss of consciousness—Capecitabine—esophageal cancer	0.00201	0.00408	CcSEcCtD
Cyclobenzaprine—Hypertension—Capecitabine—esophageal cancer	0.00197	0.00401	CcSEcCtD
Cyclobenzaprine—Hepatitis—Methotrexate—esophageal cancer	0.00196	0.00397	CcSEcCtD
Cyclobenzaprine—Chest pain—Capecitabine—esophageal cancer	0.00195	0.00396	CcSEcCtD
Cyclobenzaprine—Myalgia—Capecitabine—esophageal cancer	0.00195	0.00396	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Methotrexate—esophageal cancer	0.00194	0.00394	CcSEcCtD
Cyclobenzaprine—Anxiety—Capecitabine—esophageal cancer	0.00194	0.00394	CcSEcCtD
Cyclobenzaprine—Discomfort—Capecitabine—esophageal cancer	0.00192	0.00391	CcSEcCtD
Cyclobenzaprine—Dry mouth—Capecitabine—esophageal cancer	0.0019	0.00387	CcSEcCtD
Cyclobenzaprine—Confusional state—Capecitabine—esophageal cancer	0.00188	0.00382	CcSEcCtD
Cyclobenzaprine—Oedema—Capecitabine—esophageal cancer	0.00187	0.00379	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Cisplatin—esophageal cancer	0.00187	0.00379	CcSEcCtD
Cyclobenzaprine—Shock—Capecitabine—esophageal cancer	0.00184	0.00373	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Capecitabine—esophageal cancer	0.00183	0.00371	CcSEcCtD
Cyclobenzaprine—Tinnitus—Methotrexate—esophageal cancer	0.00182	0.00371	CcSEcCtD
Cyclobenzaprine—Tachycardia—Capecitabine—esophageal cancer	0.00182	0.0037	CcSEcCtD
Cyclobenzaprine—Asthenia—Cisplatin—esophageal cancer	0.00182	0.00369	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Capecitabine—esophageal cancer	0.0018	0.00367	CcSEcCtD
Cyclobenzaprine—Anorexia—Capecitabine—esophageal cancer	0.00178	0.00362	CcSEcCtD
Cyclobenzaprine—Hypotension—Capecitabine—esophageal cancer	0.00174	0.00354	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Cisplatin—esophageal cancer	0.00173	0.00352	CcSEcCtD
Cyclobenzaprine—Alopecia—Methotrexate—esophageal cancer	0.00173	0.00351	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.0017	0.00346	CcSEcCtD
Cyclobenzaprine—Insomnia—Capecitabine—esophageal cancer	0.00169	0.00343	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Capecitabine—esophageal cancer	0.00168	0.00341	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Methotrexate—esophageal cancer	0.00167	0.00339	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Capecitabine—esophageal cancer	0.00166	0.00338	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Capecitabine—esophageal cancer	0.00164	0.00334	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Capecitabine—esophageal cancer	0.00162	0.0033	CcSEcCtD
Cyclobenzaprine—Vomiting—Cisplatin—esophageal cancer	0.00161	0.00327	CcSEcCtD
Cyclobenzaprine—Fatigue—Capecitabine—esophageal cancer	0.00161	0.00327	CcSEcCtD
Cyclobenzaprine—Vision blurred—Methotrexate—esophageal cancer	0.0016	0.00326	CcSEcCtD
Cyclobenzaprine—Rash—Cisplatin—esophageal cancer	0.0016	0.00324	CcSEcCtD
Cyclobenzaprine—Constipation—Capecitabine—esophageal cancer	0.0016	0.00324	CcSEcCtD
Cyclobenzaprine—Dermatitis—Cisplatin—esophageal cancer	0.0016	0.00324	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Methotrexate—esophageal cancer	0.00158	0.00321	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Capecitabine—esophageal cancer	0.00154	0.00313	CcSEcCtD
Cyclobenzaprine—Malaise—Methotrexate—esophageal cancer	0.00154	0.00312	CcSEcCtD
Cyclobenzaprine—Vertigo—Methotrexate—esophageal cancer	0.00153	0.00311	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00153	0.0031	CcSEcCtD
Cyclobenzaprine—Leukopenia—Methotrexate—esophageal cancer	0.00152	0.0031	CcSEcCtD
Cyclobenzaprine—Nausea—Cisplatin—esophageal cancer	0.0015	0.00306	CcSEcCtD
Cyclobenzaprine—Urticaria—Capecitabine—esophageal cancer	0.00148	0.00301	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Capecitabine—esophageal cancer	0.00148	0.003	CcSEcCtD
Cyclobenzaprine—Convulsion—Methotrexate—esophageal cancer	0.00148	0.003	CcSEcCtD
Cyclobenzaprine—Chest pain—Methotrexate—esophageal cancer	0.00145	0.00295	CcSEcCtD
Cyclobenzaprine—Myalgia—Methotrexate—esophageal cancer	0.00145	0.00295	CcSEcCtD
Cyclobenzaprine—Discomfort—Methotrexate—esophageal cancer	0.00143	0.00291	CcSEcCtD
Cyclobenzaprine—Confusional state—Methotrexate—esophageal cancer	0.0014	0.00285	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methotrexate—esophageal cancer	0.00139	0.00282	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Capecitabine—esophageal cancer	0.00138	0.00279	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Methotrexate—esophageal cancer	0.00136	0.00276	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Methotrexate—esophageal cancer	0.00134	0.00273	CcSEcCtD
Cyclobenzaprine—Asthenia—Capecitabine—esophageal cancer	0.00134	0.00272	CcSEcCtD
Cyclobenzaprine—Anorexia—Methotrexate—esophageal cancer	0.00132	0.00269	CcSEcCtD
Cyclobenzaprine—Pruritus—Capecitabine—esophageal cancer	0.00132	0.00268	CcSEcCtD
Cyclobenzaprine—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00131	0.00274	CbGpPWpGaD
Cyclobenzaprine—HTR2A—G alpha (q) signalling events—ANXA1—esophageal cancer	0.00131	0.00273	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.0013	0.00272	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.0013	0.00271	CbGpPWpGaD
Cyclobenzaprine—Hypotension—Methotrexate—esophageal cancer	0.0013	0.00264	CcSEcCtD
Cyclobenzaprine—Carbamazepine—ABCB1—esophageal cancer	0.00129	0.0442	CrCbGaD
Cyclobenzaprine—Diarrhoea—Capecitabine—esophageal cancer	0.00128	0.0026	CcSEcCtD
Cyclobenzaprine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00127	0.00265	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00127	0.00265	CbGpPWpGaD
Cyclobenzaprine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00127	0.00257	CcSEcCtD
Cyclobenzaprine—Insomnia—Methotrexate—esophageal cancer	0.00126	0.00255	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.00125	0.00261	CbGpPWpGaD
Cyclobenzaprine—Paraesthesia—Methotrexate—esophageal cancer	0.00125	0.00254	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Methotrexate—esophageal cancer	0.00124	0.00252	CcSEcCtD
Cyclobenzaprine—HTR2A—G alpha (q) signalling events—GHRL—esophageal cancer	0.00124	0.00259	CbGpPWpGaD
Cyclobenzaprine—Somnolence—Methotrexate—esophageal cancer	0.00124	0.00251	CcSEcCtD
Cyclobenzaprine—Dizziness—Capecitabine—esophageal cancer	0.00123	0.00251	CcSEcCtD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00123	0.00257	CbGpPWpGaD
Cyclobenzaprine—Dyspepsia—Methotrexate—esophageal cancer	0.00122	0.00249	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Methotrexate—esophageal cancer	0.00121	0.00245	CcSEcCtD
Cyclobenzaprine—Fatigue—Methotrexate—esophageal cancer	0.0012	0.00243	CcSEcCtD
Cyclobenzaprine—Vomiting—Capecitabine—esophageal cancer	0.00119	0.00241	CcSEcCtD
Cyclobenzaprine—Rash—Capecitabine—esophageal cancer	0.00118	0.00239	CcSEcCtD
Cyclobenzaprine—Dermatitis—Capecitabine—esophageal cancer	0.00118	0.00239	CcSEcCtD
Cyclobenzaprine—Headache—Capecitabine—esophageal cancer	0.00117	0.00238	CcSEcCtD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.00117	0.00244	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00117	0.00243	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.00116	0.00243	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.00115	0.00239	CbGpPWpGaD
Cyclobenzaprine—Feeling abnormal—Methotrexate—esophageal cancer	0.00115	0.00233	CcSEcCtD
Cyclobenzaprine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00115	0.00239	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.00114	0.00238	CbGpPWpGaD
Cyclobenzaprine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00114	0.00231	CcSEcCtD
Cyclobenzaprine—Nausea—Capecitabine—esophageal cancer	0.00111	0.00225	CcSEcCtD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.00111	0.00231	CbGpPWpGaD
Cyclobenzaprine—Urticaria—Methotrexate—esophageal cancer	0.0011	0.00224	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Methotrexate—esophageal cancer	0.0011	0.00223	CcSEcCtD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.0011	0.00229	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00109	0.00228	CbGpPWpGaD
Cyclobenzaprine—Chlorprothixene—ABCB1—esophageal cancer	0.00108	0.0371	CrCbGaD
Cyclobenzaprine—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00108	0.00225	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00108	0.00225	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.00106	0.00221	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00104	0.00218	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00104	0.00217	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00102	0.00214	CbGpPWpGaD
Cyclobenzaprine—Hypersensitivity—Methotrexate—esophageal cancer	0.00102	0.00208	CcSEcCtD
Cyclobenzaprine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00101	0.00211	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.001	0.00209	CbGpPWpGaD
Cyclobenzaprine—Asthenia—Methotrexate—esophageal cancer	0.000997	0.00203	CcSEcCtD
Cyclobenzaprine—Trimipramine—ABCB1—esophageal cancer	0.000997	0.0343	CrCbGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000984	0.00206	CbGpPWpGaD
Cyclobenzaprine—Pruritus—Methotrexate—esophageal cancer	0.000983	0.002	CcSEcCtD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000971	0.00203	CbGpPWpGaD
Cyclobenzaprine—Promethazine—ABCB1—esophageal cancer	0.000959	0.033	CrCbGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000958	0.002	CbGpPWpGaD
Cyclobenzaprine—Tamoxifen—ABCB1—esophageal cancer	0.000953	0.0328	CrCbGaD
Cyclobenzaprine—Diarrhoea—Methotrexate—esophageal cancer	0.000951	0.00193	CcSEcCtD
Cyclobenzaprine—Doxepin—ABCB1—esophageal cancer	0.00095	0.0327	CrCbGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000947	0.00198	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000931	0.00194	CbGpPWpGaD
Cyclobenzaprine—Dizziness—Methotrexate—esophageal cancer	0.000919	0.00187	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000901	0.00188	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000891	0.00186	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000884	0.00185	CbGpPWpGaD
Cyclobenzaprine—Vomiting—Methotrexate—esophageal cancer	0.000883	0.0018	CcSEcCtD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000882	0.00184	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000879	0.00184	CbGpPWpGaD
Cyclobenzaprine—Rash—Methotrexate—esophageal cancer	0.000876	0.00178	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methotrexate—esophageal cancer	0.000875	0.00178	CcSEcCtD
Cyclobenzaprine—Headache—Methotrexate—esophageal cancer	0.00087	0.00177	CcSEcCtD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000865	0.00181	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000844	0.00176	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000842	0.00176	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000831	0.00173	CbGpPWpGaD
Cyclobenzaprine—Nausea—Methotrexate—esophageal cancer	0.000825	0.00168	CcSEcCtD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00082	0.00171	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000817	0.00171	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000811	0.00169	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000806	0.00168	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—GNG7—esophageal cancer	0.000804	0.00168	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000803	0.00168	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000787	0.00164	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.000763	0.00159	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.00076	0.00159	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000755	0.00158	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000749	0.00156	CbGpPWpGaD
Cyclobenzaprine—Imipramine—ABCB1—esophageal cancer	0.000739	0.0254	CrCbGaD
Cyclobenzaprine—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000737	0.00154	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000736	0.00154	CbGpPWpGaD
Cyclobenzaprine—Amitriptyline—ABCB1—esophageal cancer	0.000734	0.0253	CrCbGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000721	0.0015	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000718	0.0015	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000715	0.00149	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—CXCL2—esophageal cancer	0.000709	0.00148	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000708	0.00148	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000688	0.00144	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—GDI2—esophageal cancer	0.000675	0.00141	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000675	0.00141	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000666	0.00139	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—ANXA1—esophageal cancer	0.000659	0.00138	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000655	0.00137	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000655	0.00137	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—SST—esophageal cancer	0.000641	0.00134	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—GHRL—esophageal cancer	0.000625	0.0013	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000619	0.00129	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000608	0.00127	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.0006	0.00125	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000589	0.00123	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000587	0.00123	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000582	0.00122	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000572	0.00119	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000571	0.00119	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000564	0.00118	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000558	0.00117	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000558	0.00117	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000552	0.00115	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000523	0.00109	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000491	0.00102	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KMT2D—esophageal cancer	0.000488	0.00102	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000478	0.000998	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—AKAP13—esophageal cancer	0.000475	0.000991	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000469	0.00098	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000463	0.000967	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—GNG7—esophageal cancer	0.000455	0.000949	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000441	0.000922	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000435	0.000909	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000435	0.000908	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PDE4D—esophageal cancer	0.000434	0.000906	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—GNG7—esophageal cancer	0.000413	0.000862	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—CXCL2—esophageal cancer	0.0004	0.000836	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—WWOX—esophageal cancer	0.000398	0.000831	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000396	0.000828	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FKBP1A—esophageal cancer	0.000378	0.00079	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000372	0.000778	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—WIF1—esophageal cancer	0.00037	0.000772	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CXCL2—esophageal cancer	0.000364	0.000759	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000363	0.000757	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000363	0.000757	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—SST—esophageal cancer	0.000362	0.000756	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—GHRL—esophageal cancer	0.000353	0.000737	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000346	0.000722	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000341	0.000713	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—ANXA1—esophageal cancer	0.000338	0.000706	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—SST—esophageal cancer	0.000329	0.000687	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000324	0.000676	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—GHRL—esophageal cancer	0.000321	0.000669	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PFN1—esophageal cancer	0.000319	0.000667	CbGpPWpGaD
Cyclobenzaprine—HTR2A—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000314	0.000656	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CA1—esophageal cancer	0.000308	0.000644	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000308	0.000644	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000307	0.000642	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000307	0.000642	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ELMO1—esophageal cancer	0.000287	0.000599	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CA2—esophageal cancer	0.000282	0.000589	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000281	0.000587	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—AKAP13—esophageal cancer	0.00028	0.000585	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000275	0.000574	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000262	0.000548	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000262	0.000548	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000261	0.000546	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CA1—esophageal cancer	0.000261	0.000546	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000259	0.00054	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PDE4D—esophageal cancer	0.000256	0.000535	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—GNG7—esophageal cancer	0.000244	0.000509	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CA2—esophageal cancer	0.000239	0.000499	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000237	0.000495	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000237	0.000495	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000234	0.000488	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.00023	0.00048	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—XIAP—esophageal cancer	0.000229	0.000477	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000222	0.000464	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000222	0.000464	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.00022	0.000459	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.00022	0.000459	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CTNNA1—esophageal cancer	0.000216	0.000451	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CXCL2—esophageal cancer	0.000215	0.000449	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000214	0.000446	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000208	0.000435	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CA1—esophageal cancer	0.000202	0.000421	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000202	0.000421	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PSME1—esophageal cancer	0.000201	0.000419	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PSME2—esophageal cancer	0.000201	0.000419	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ANXA1—esophageal cancer	0.0002	0.000417	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000199	0.000415	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000199	0.000415	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ADH1B—esophageal cancer	0.000195	0.000407	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SST—esophageal cancer	0.000194	0.000406	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000191	0.000398	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—GHRL—esophageal cancer	0.000189	0.000395	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOTCH3—esophageal cancer	0.000189	0.000395	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FBXW7—esophageal cancer	0.000186	0.000389	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TYMP—esophageal cancer	0.000186	0.000389	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CA2—esophageal cancer	0.000184	0.000385	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000183	0.000383	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000182	0.00038	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	0.000181	0.000378	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALOX15—esophageal cancer	0.000176	0.000369	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000173	0.000361	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000171	0.000358	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000171	0.000358	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	0.00017	0.000355	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTO1—esophageal cancer	0.000168	0.000352	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TPI1—esophageal cancer	0.000168	0.000352	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000162	0.000338	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALDOB—esophageal cancer	0.000161	0.000337	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GAPDH—esophageal cancer	0.000155	0.000324	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000154	0.000322	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CRABP1—esophageal cancer	0.000154	0.000322	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000152	0.000318	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	0.000151	0.000315	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.00015	0.000314	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GNG7—esophageal cancer	0.000146	0.000306	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000144	0.000302	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000144	0.000302	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000144	0.0003	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	0.000143	0.000298	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000142	0.000297	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000142	0.000297	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.00014	0.000292	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALDH2—esophageal cancer	0.000137	0.000287	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000136	0.000284	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTT1—esophageal cancer	0.000131	0.000273	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TPI1—esophageal cancer	0.00013	0.000271	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.00013	0.000271	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	0.000129	0.000269	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000129	0.000268	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000125	0.00026	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000123	0.000256	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ENO1—esophageal cancer	0.000122	0.000255	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTGS1—esophageal cancer	0.000122	0.000255	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PSME2—esophageal cancer	0.000121	0.000252	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PSME1—esophageal cancer	0.000121	0.000252	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.00012	0.00025	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000119	0.000248	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	0.000117	0.000244	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000115	0.000241	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GNG7—esophageal cancer	0.000113	0.000236	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KDR—esophageal cancer	0.000112	0.000233	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALDH2—esophageal cancer	0.000106	0.000221	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000105	0.00022	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000105	0.00022	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	0.000105	0.00022	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	0.000104	0.000217	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ABCB1—esophageal cancer	0.000101	0.000211	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTT1—esophageal cancer	0.000101	0.00021	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	9.96e-05	0.000208	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	9.78e-05	0.000204	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	9.53e-05	0.000199	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.44e-05	0.000197	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ENO1—esophageal cancer	9.44e-05	0.000197	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	9.37e-05	0.000196	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PSME1—esophageal cancer	9.3e-05	0.000194	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PSME2—esophageal cancer	9.3e-05	0.000194	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	8.95e-05	0.000187	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HMOX1—esophageal cancer	8.92e-05	0.000186	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.75e-05	0.000183	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ABCB1—esophageal cancer	8.57e-05	0.000179	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	8.53e-05	0.000178	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	8.13e-05	0.00017	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.03e-05	0.000168	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	7.98e-05	0.000167	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.55e-05	0.000158	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	7.05e-05	0.000147	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HMOX1—esophageal cancer	6.89e-05	0.000144	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	6.82e-05	0.000142	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CREBBP—esophageal cancer	6.76e-05	0.000141	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.61e-05	0.000138	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EP300—esophageal cancer	6.49e-05	0.000136	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.48e-05	0.000135	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NOS3—esophageal cancer	6.05e-05	0.000126	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CREBBP—esophageal cancer	5.72e-05	0.00012	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MYC—esophageal cancer	5.66e-05	0.000118	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTGS2—esophageal cancer	5.53e-05	0.000116	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	5.53e-05	0.000116	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NOS3—esophageal cancer	5.13e-05	0.000107	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	4.8e-05	0.0001	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTGS2—esophageal cancer	4.69e-05	9.79e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TP53—esophageal cancer	4.65e-05	9.7e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—EP300—esophageal cancer	4.6e-05	9.61e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.42e-05	9.23e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NOS3—esophageal cancer	3.96e-05	8.26e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—EP300—esophageal cancer	3.9e-05	8.14e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.62e-05	7.56e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.4e-05	7.11e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—EP300—esophageal cancer	3.01e-05	6.28e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.88e-05	6.02e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.23e-05	4.65e-05	CbGpPWpGaD
